Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | NPC1 | O15118 | 1/20 | 0.86 |
| ▸ | GMNN | O75496 | 1/20 | 0.86 |
| ▸ | USP2 | O75604 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | IDE | P14735 | 1/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617723 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL30368905 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL30718914 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL30718949 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| Palmitoyl Dopamine SCHEMBL30438287 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL30582326 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL10617939 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL3326638 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL3325854 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A | |
| SCHEMBL671000 | 1.00 | TRPV1 (1.00) | TRPV1MAPTHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879891-A | Method for evaluating PE (polyethylene) based on intestinal flora | 广州市番禺区妇幼保健院(广州市番禺区何贤纪念医院) | 2024-11-01 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-3207091-B1 | IMPROVED RUBBER COMPOSITIONS AND USES THEREOF | BRIDGESTONE CORP (JP) | 2019-09-18 | — | — | EP | claimed |
| CN-118879891-A | Method for evaluating PE (polyethylene) based on intestinal flora | 广州市番禺区妇幼保健院(广州市番禺区何贤纪念医院) | 2024-11-01 | — | — | CN | disclosed |
| WO-2024124172-A1 | COMPOSITIONS AND METHODS FOR STIMULATING AND/OR ENHANCING EXERCISE MOTIVATION AND/OR PHYSICAL PERFORMANCE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20200323814-A1 | MEDICAL COMPOUND | VERA SALUS RICERCA S.R.L. (IT) | 2020-10-15 | — | — | US | disclosed |
| WO-2019008537-A9 | MEDICAL COMPOUNDS | VERA SALUS RICERCA S.R.L. (IT) | 2020-02-20 | — | — | WO | disclosed |
| WO-2019008537-A1 | MEDICAL COMPOUNDS | VERA SALUS RICERCA S.R.L. (IT) | 2019-01-10 | — | — | WO | disclosed |
| EP-2618802-A1 | COSMETIC TREATMENT PROCESS USING ORTHO-DIPHENOL DERIVATIVES, NOVEL COMPOUNDS AND COSMETIC COMPOSITION COMPRISING SAME | L'Oréal (FR) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038334-A1 | COSMETIC TREATMENT PROCESS USING ORTHO-DIPHENOL DERIVATIVES, NOVEL COMPOUNDS AND COSMETIC COMPOSITION COMPRISING SAME | L'OREAL (FR) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038334-A1 | COSMETIC TREATMENT PROCESS USING ORTHO-DIPHENOL DERIVATIVES, NOVEL COMPOUNDS AND COSMETIC COMPOSITION COMPRISING SAME | L'OREAL (FR) | 2012-03-29 | — | — | WO | disclosed |
| US-20100130603-A1 | MEDICAMENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DERMATOSIS RESULTING FROM EXCESSIVELY ADVANCED KERATINIZATION | KYOTO UNIVERSITY (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2127673-A1 | PHARMACEUTICAL AGENT FOR PREVENTION AND TREATMENT OF SKIN DISEASE INDUCED BY ACCELERATED KERATINIZATION | Kyoto University (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323814-A1 | MEDICAL COMPOUND | MTNR1B, CBR1, MTNR1A | TRPV1 2045/4885MAPT 3940/4885HSD17B10 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.